Jun 14 1999 9:17AM
SOURCE: Reuters Financial News Service
Monsanto (MTC) Searle unit hires former FDA man
CHICAGO, June 14 (Reuters) - Pharmaceutical company G. D.
Searle & Co., a division of Monsanto Co., said Monday that
it named Michael Friedman, M.D., senior vice president,
clinical affairs, effective in July.
Friedman was most recently at the U.S. Food and Drug
Administration, serving in a variety of roles, including
acting commissioner. He will be responsible for directing
strategy and implementation of clinical research.
Searle said Friedman will support the management of
its entire portfolio of clinical research products, and
expedite the development of novel, value-added
therapeutics. In addition, he will advise and facilitate
the development of nutritional products within Monsanto's
Life Sciences program.
Friedman's appointment follows the retirement of John
Alexander, M.D., who has led Searle's worldwide clinical
trial development programs since 1991. The most recent
clinical development success resulted in the December 1998
approval of Celebrex, which has had more than five million
prescriptions written to date since its launch earlier this
((--Chicago Equities News at 312 408 8787,
Do You Yahoo!?
Get your free @yahoo.com address at http://mail.yahoo.com
To Unsubscribe: Email email@example.com with the command
"unsubscribe sanet-mg". If you receive the digest format, use the command
To Subscribe to Digest: Email firstname.lastname@example.org with the command
All messages to sanet-mg are archived at: